CTLA4 and melanoma: To date, in-depth characterization of two of the immune checkpoint proteins and their regulatory effects yielded a design of drugs which were approved for treatment of advanced melanoma, CTLA-4 and PD-1 inhibitory proteins and PD-L1, a ligand of PD-1.